NCT05276570View on ClinicalTrials.gov

Study of ARO-RAGE in Healthy Subjects and Patients With Inflammatory Lung Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

127

Participants

Timeline

Start Date

June 29, 2022

Primary Completion Date

April 16, 2025

Study Completion Date

April 16, 2025

Conditions
Asthma
Interventions
DRUG

ARO-RAGE

single or multiple doses of ARO-RAGE by inhalation of nebulized solution

DRUG

Placebo

calculated volume to match active treatment by inhalation of nebulized solution

Trial Locations (8)

622

Research Site 3, Auckland

1010

Research Site 1, Auckland

1051

Research Site 2, Auckland

6009

Research Site 1, Nedlands

10700

Research Site 1, Bangkok Noi

31-455

Research Site 2, Krakow

32-600

Research Site 3, Oświęcim

08017

Research Site 1, Barcelona

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY